• 1
    Watkins AD. The role of alternative therapies in the treatment of allergic diseases. Clin Exp Allergy 1994;24:81325.
  • 2
    Holt PG, Batty JE, Turner KJ. Inhibition of specific IgE responses in mice by pre-exposure to inhaled antigen. Immunology 1981;42:40917.
  • 3
    Holt PG, Scdgewick JD. Suppression of IgE responses following inhalation of antigen. A natural homeostatic mechanism which limits sensitization to aeroallergens. Immunol Today 1987;8:1426.
  • 4
    Holt PG, Britten D, Sedgewick JD. Suppression of IgE responses by antigen inhalation: studies on the role of genetic and environmental factors. Immunology 1987;60:97102.
  • 5
    Holt PG, McMenamin C. Defence against allergic sensitization in healthy lung: the role of inhalation tolerance. Clin Exp Allergy 1989;19:5562.
  • 6
    Mowart AM. The regulation of immune response to dietary proteins. Immunol Today 1987;8:936.
  • 7
    Holt PG, Vines J, Britten D. Sublingual allergen administration. I. Selective suppression of IgE production in rats by high allergen doses. Clin Allergy 1988;18:22934.
  • 8
    Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:123740.
  • 9
    Eriksson K, Ahlfors E, George-Chandy A, Kaiserlian D, Czerkinsky C. Antigen presentation in the murine oral epithelium. Immunology 1996;88:14752.
  • 10
    Vanwilsem EJ, Vanhoogstraten IM, Breve J, Scheper RJ, Kraal G. Dendritic cells of the oral mucosa and the induction of oral tolerance. A local affair. Immunology 1994;83:12832.
  • 11
    Hasseus B, Dahlgren U, Bergenholtz G, Jontell M. Antigen presenting capacity of Langerhans cells from rat oral epithelium. J Oral Pathol Med 1995;24:5660.
  • 12
    Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177:11991204.
  • 13
    Macatinia SE, Hosken NA, Litton M, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995;154:50719.
  • 14
    Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the major Parietaria judaica (Par j 1) allergen administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol 1997;100:1229.
  • 15
    Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993;91:7347.
  • 16
    Malling H-J, Weeke B. Immunotherapy. EAACI Position paper. Allergy 1993;38 Suppl 14:945.
  • 17
    Hejjaoui J, Ferrando R, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol 1992;89:92533.
  • 18
    Tabar AI, Garcia BE, Rodriguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy 1993;48:4503.
  • 19
    Curtis HH. The immunizing cure of hay fever. Med News (NY) 1900;77:1618.
  • 20
    Black JH. The oral administration of pollen. J Lab Clin Med 1927;12:11569.
  • 21
    Feinberg SM, Foran FL, Lichtenstein MR. Oral pollen therapy in ragweed pollinosis. J Am Med Assoc 1940;115:239.
  • 22
    Committee on the Safety of Medicine. CSM update. De-sensitizing vaccines. BMJ 1986;293:948.
  • 23
    Greenberg MA, Kaufman CR, González GE. Late and immediate systemic allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol 1986;77:86570.
  • 24
    Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy and skin testing. J Allergy Clin Immunol 1987;79:66077.
  • 25
    Dreborg S, editors.Frew A. Allergen standardization and skin tests. Allergy 1993;48 Suppl 14:4982.
  • 26
    Giovane AL, Bardare M, Passalacqua G, et al. A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 1994;24:539.
  • 27
    Malling H-J. New ideas in allergen-specific immunotherapy. Am J Rhinol 1990;4:1558.
  • 28
    Johansson SGO, Deuschl H, Zetterström O. Use of glutar-aldehyde-modified timothy grass pollen extract in nasal hyposensitisation treatment of hay fever. Int Arch Allergy Appl Immunol 1979;60:44760.
  • 29
    Nickelsen JA, Goldstein S, Mueller U, Wypych J, Reisman RE, Arbesman CE. Local intranasal immunotherapy for ragweed allergic rhinitis, I. Clinical response. J Allergy Clin Immunol 1981;68:3340.
  • 30
    Welsh PW, Zimmermann EM, Yunginger JW, Kern EB, Gleich GJ. Preseasonal intranasal immunotherapy with nebulized short ragweed extract. J Allergy Clin Immunol 1981;67:23742.
  • 31
    Schumacher MJ, Pain MC. Intranasal immunotherapy and polymerized grass pollen allergens. Allergy 1982;37:2418.
  • 32
    Georgitis JW, Reisman RE, Clayton WF, Mueller UR, Wypych JI, Arbesman CE. Local intranasal immunotherapy for grass-allergic rhinitis. J Allergy Clin Immunol 1983;71:716.
  • 33
    Georgitis JW, Clayton WF, Wypych JI, Barde SH, Reisman RE. Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts. J Allergy Clin Immunol 1984;74:694700.
  • 34
    Andri L, Senna GE, Betteli C, et al. Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study. Allergy 1992;47:31823.
  • 35
    Andri L, Senna G, Betteli C, Givanni S, Andri G, Falagiani P. Local nasal immunotherapy for Dermatophagoides-indueed rhinitis: efficacy of a powder extract. J Allergy Clin Immunol 1993;91:98796.
  • 36
    Passalacqua G, Albano M, Ruffoni S, et al. Nasal immunotherapy to Parietaria: evidence of reduction of local inflammation. Am J Respir Crit Care Med 1995;152:4616.
  • 37
    D'Amato G, Lobefalo G, Liccardi G, Cazzola M. A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin Exp Allergy 1995;25:1418.
  • 38
    Andri L, Senna G, Andri G, et al. Local nasal immunotherapy for birch allergic rhinitis with extract in powder form. Clin Exp Allergy 1995;25:10929.
  • 39
    Andri L, Senna G, Betteli C, et al. Local nasal immunotherapy with extract in powder form is effective and safe in grass-pollen rhinitis. A double blind study. J Allergy Clin Immunol 1996;97:3441.
  • 40
    Cirla AM, Sforza N, Roffi GP, et al. Preseasonal intranasal immunotherapy in birch-alder allergic rhinitis. A double-blind study. Allergy 1996;51:299305.
  • 41
    Bardare M, Zani G, Novembre E, Vierucci A. Local nasal immunotherapy with a powder extract for grass pollen induced rhinitis in pediatric ages: a controlled study. J Investig Allergol Immunol 1996;6:35963.
  • 42
    Metha SB, Morrison Smith J. Nasal hyposensitization and hay fever. Clin Allergy 1975;5:27984.
  • 43
    Georgitis JW, Nickelsen JA, Wypych JI, Kane JH, Reisman RE. Local nasal immunotherapy. Efficacy of low-dose aqueous ragweed extract. J Allergy Clin Immunol 1985;75:496500.
  • 44
    Georgitis JW, Nickelsen JA, Wypych JI, Barde SH, Clayton WF, Reisman RE. Local intranasal immunotherapy with high-dose polymerized ragweed extract. Int Arch Allergy Appl Immunol 1986;81:1703.
  • 45
    Ariano R, Panzani RC, Chiapella M, Augeri G, Falagiani P. Local immunotherapy of seasonal allergic rhinitis in children due to Parietaria pollen. A preliminary report. Pediatr Asthma Allergy Immunol 1993;7:22737.
  • 46
    Welsh PW, Butterfield JH. Yunginger W, Agarwal MK, Gjeich GJ. Allergen controlled study of intranasal immunotherapy for ragweed hay fever. J Allergy Clin Immunol 1983;71:45460.
  • 47
    Gasparini A, Di Franco G, Malavenda A. Preliminary evaluation of the nasal local specific immunotherapy in mite-sensitive respiratory patients. Perspect ENT Immunol 1991;5:2933.
  • 48
    Filiaci F, Zambetti G, Lo Vecchio A. Specific local immunotherapy with macronized dust in the treatment of seasonal allergic rhinopathy caused by Gramineae. Perspect ENT Immunol 1989;3:1706.
  • 49
    Gaglani B, Borish L, Bartelson BL, Buchmeier A, Keller L, Nelson HS. Nasal immunotherapy in weed-induced rhinitis. Ann Allergy Asthma Immunol 1997;79:25965.
  • 50
    Passalacqua G, Albano M, Pronzato C, et al. Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects. Clin Exp Allergy 1997;27:9048.
  • 51
    Crimi E, Voltolini S, Troise C, et al. Local immunotherapy with Dermatophagoides extract in asthma. J Allergy Clin Immunol 1991;87:7218.
  • 52
    Tari MG, Mancino M, Monti G. Immunotherapy by inhalation of allergen in powder in house dust allergic asthma: a double-blind study. J Investig Allergol Clin Immunol 1992;2:5967.
  • 53
    Taudorf E, Weeke B. Orally administered grass pollen. Allergy 1983;38:5614.
  • 54
    Björkstén B, Möller C, Broberger U, et al. Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract. Allergy 1986;41:2905.
  • 55
    Creticos PS, Naclerio RM, Adkinson F, Norman PS. Efficacy, safety and kinetics of oral ragweed immunotherapy in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1990;85:165.
  • 56
    Leng X, Fu YX, Ye ST, Duan SQ. A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to pollen allergen and serum-specific IgE antibody. Ann Allergy 1990;64:2731.
  • 57
    Cooper PJ, Darbyshire J, Nunn AJ, Warner JO. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children. Clin Allergy 1984;14:54150.
  • 58
    Taudorf E, Laursen LC, Djurup R, et al. Oral administration of grass pollen to hay fever patients. An efficacy study in oral hyposensitization. Allergy 1985;40:32135.
  • 59
    Möller C, Dreborg S, Lanner Å, Björkstén B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy 1986;41:2719.
  • 60
    Mosbech H, Dreborg S, Madsen F, et al. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo controlled study. Allergy 1987;42:4515.
  • 61
    Taudorf E. Laursen LC. Lanner Å, et al. Oral immunotherapy in birch pollen hay fever. J Allergy Clin Immunol 1987;80:15361.
  • 62
    Oppenheimer J, Areson JG, Nelson HS. Safety and efficacy of oral immunotherapy with standardized cat extract. J Allergy Clin Immunol 1994;93:617.
  • 63
    Einarsson R, Renck B, Taudorf E. In vitro studies of degradation of birch and timothy pollen allergen preparations by human duodenal juice. Allergy 1988;43:46972.
  • 64
    van Deusen MA, Angelini BL, Cordoro KM, Seiler BA, Wood L, Skoner DP. Efficacy and safety of oral immunotherapy with short ragweed extract. Ann Allergy Asthma Immunol 1997;78:57380.
  • 65
    Litwin A, Flanagan M, Entis G, et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J Allergy Clin Immunol 1997;100:308.
  • 66
    Taudorf E, Laursen L, Lanner A, Björkstén B, Dreborg S, Weeke B. Specific IgE, IgG, and IgA antibody response to oral immunotherapy in birch pollinosis. J Allergy Clin Immunol 1989;83:58994.
  • 67
    Scadding K, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin Allergy 1986;16:48391.
  • 68
    Reilly D, Taylor MA, Beattie NGM, et al. Is evidence for homeopathy reproducible Lancet 1994;344:16016.
  • 69
    van Niekerk CH, De Wet JI. Efficacy of grass-maize pollen oral immunotherapy in patients with seasonal hay fever: a double blind study. Clin Allergy 1987;17:50713.
  • 70
    Feliziani V, Marfisi RM, Parmiani S. Rush immunotherapy with sublingual administration of grass allergen extract. Allergol Immunopathol (Madr) 1993;21:1738.
  • 71
    Nelson HS, Oppenheimer J, Vatsia GA. Bucheimer A. A double blind placebo controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993;92:22936.
  • 72
    Casanovas M, Guerra F, Moreno C, Miguel R, Maranon F, Daza JC. Double blind placebo controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. J Investig Allergol Clin Immunol 1994;4:30514.
  • 73
    D'Ambrosio FP, Ricciardi L, Isola S, Puccinelli P, Musarra A. Rush sublingual immunotherapy in Parietaria allergic patients. Allergol Immunopathol (Madr) 1996;24:14651.
  • 74
    Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol Immunopathol (Madr) 1990;18:27784.
  • 75
    Sabbah A, Hassoun S, Le Sellin J, André C, Sicard H. A double blind placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:30913.
  • 76
    Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr) 1995;23:22430.
  • 77
    Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen induced rhinitis: a double blind study. J Investig Allergol Clin Immunol 1995;5:2530.
  • 78
    Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract ( in children. Pediatr Allergy Immunol 1997;8:217.
  • 79
    Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunetivitis. Lancet 1998;351:62932.
  • 80
    Rebien W, Puttonen E, Maasch HJ. Stix E, Wahn U. Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospeetive study. Eur J Pediatr 1982;138:3414.
  • 81
    Palacios AS, Medina FS. Rua-Figueroa AL, Millares CB, Santos SR, Marrero JAG. Comparative clinical-immunological study of oral and subcutaneous immunotherapy in children with extrinsic bronchial asthma. Allergol Immunopathol (Madr) 1989;17:3239.
  • 82
    Urbanek R, Bürgelin KH, Kahle W, Wahn U. Oral immunotherapy with grass pollen in enterosoluble capsules. Eur J Pediatr 1990;149:54550.
  • 83
    Moscato G, Rossi G, Dellabianca A, Pisati A, Vinci G, Biale C. Local immunotherapy by inhalation of a powder extract in asthma due to house dust mite Dermatophagoides pteronyssinus: a double-blind comparison with parenteral immunotherapy. J Investig Allergol Clin Immunol 1991;1:38394.
  • 84
    Corbetta L, Pesiri P, Ferro G, Mander A. Improvement of fog and exercise induced asthma after local and subcutaneous immunotherapy in mite asthma. Allergol Immunopathol (Madr) 1992;20:606.
  • 85
    Piazza I, Bizzaro N. Humoral response to subcutaneous, oral, and nasal immunotherapy for allergic rhinitis due to Dermatophagoides pteronyssinus. Ann Allergy 1993;71:4619.
  • 86
    Bernadis P, Agnoletto M, Puccinelli P, Parmiani S, Pozzan M. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients, J Investig Allergol Clin Immunol 1996;6:5562.
  • 87
    Quirino T, Lemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996;26:125361.
  • 88
    Horak F, Wheeler AW. Oral hyposensitisation with enteric-coated allergens as extension therapy following a basic subcutaneous course of injections. Int Arch Appl Immunol 1987;84:748.
  • 89
    Trede NS, Urbanek R. Combination of parenteral and oral immunotherapy in grass pollen-allergic children. A double-blind controlled study of clinical and immunological efficacy. Allergy 1989;44:27280.